Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
CLLS Cellectis S.A. daily Stock Chart
CLLS [NASD]
Cellectis S.A.
Healthcare | Biotechnology | France
statements
Index- P/E- EPS (ttm)-1.89 Insider Own- Shs Outstand43.31M Perf Week-3.57%
Market Cap737.57M Forward P/E- EPS next Y-2.54 Insider Trans- Shs Float31.97M Perf Month-7.70%
Income-80.10M PEG- EPS next Q-0.74 Inst Own27.90% Short Float0.71% Perf Quarter24.40%
Sales20.00M P/S36.88 EPS this Y30.70% Inst Trans-0.51% Short Ratio1.74 Perf Half Y38.57%
Book/sh8.03 P/B2.12 EPS next Y-12.90% ROA-16.00% Target Price40.00 Perf Year-2.41%
Cash/sh- P/C- EPS next 5Y- ROE-21.30% 52W Range9.50 - 20.84 Perf YTD-0.53%
Dividend- P/FCF- EPS past 5Y-21.20% ROI-25.60% 52W High-18.28% Beta1.91
Dividend %- Quick Ratio7.90 Sales past 5Y11.00% Gross Margin- 52W Low79.26% ATR0.68
Employees149 Current Ratio8.00 Sales Q/Q-44.60% Oper. Margin- RSI (14)47.63 Volatility3.01% 3.83%
OptionableYes Debt/Eq0.14 EPS Q/Q71.80% Profit Margin- Rel Volume0.36 Prev Close17.47
ShortableYes LT Debt/Eq0.13 EarningsMar 09 BMO Payout- Avg Volume130.00K Price17.03
Recom1.70 SMA200.43% SMA50-0.17% SMA20015.84% Volume47,444 Change-2.52%
Oct-30-19Resumed Guggenheim Buy $28
Aug-09-19Initiated BTIG Research Buy $37
May-24-19Resumed Citigroup Neutral $22
Mar-14-19Initiated William Blair Outperform
Dec-19-18Initiated Goldman Neutral
Jul-16-18Initiated Barclays Overweight $50
Mar-16-18Initiated Guggenheim Neutral
Sep-05-17Reiterated Wells Fargo Outperform $33 → $40
Sep-05-17Downgrade SunTrust Buy → Hold
Mar-02-17Initiated Instinet Buy $49
Feb-28-17Initiated Wells Fargo Outperform
Apr-05-16Initiated Ladenburg Thalmann Buy $45
Mar-02-16Initiated Sun Trust Rbsn Humphrey Buy
Jul-20-15Initiated BofA/Merrill Buy $50
Apr-20-15Initiated Piper Jaffray Overweight $42
Apr-20-15Initiated Jefferies Buy $46
Feb-18-20 04:30PM  Cellectis and Servier Expand Collaboration on UCART19 Products Business Wire
Feb-07-20 05:00PM  Cellectis: Monthly Information on Share Capital and Company Voting Rights Business Wire
Jan-27-20 11:01PM  Imagine Owning Cellectis (EPA:ALCLS) And Wondering If The 43% Share Price Slide Is Justified Simply Wall St.
Jan-15-20 04:30PM  First Patient Dosed with Cellectis New Allogeneic UCART123 Product Candidate for Relapsed/Refractory Acute Myeloid Leukemia Business Wire
Jan-13-20 04:15PM  Why This Biotech Stock Is Planning To Gene Edit Its Cancer Drugs Investor's Business Daily
Jan-09-20 04:30PM  Cellectis: Monthly Information on Share Capital and Company Voting Rights Business Wire
Jan-06-20 04:30PM  Cellectis: An Expert Review on Allogeneic CAR-T for Cancer Published in Nature Reviews Drug Discovery Business Wire
Jan-02-20 09:16AM  Keysight, Analog Devices, Alexion, Amarin and Cellectis highlighted as Zacks Bull and Bear of the Day Zacks
Dec-31-19 08:45AM  3 Biotech Stocks Likely to Maintain Solid Momentum in 2020 Zacks
Dec-17-19 11:13AM  Gilead's Second CAR-T Treatment Suffers the Same Issues as Yescarta GuruFocus.com +15.28%
Dec-02-19 04:30PM  1st Patient Dosed with Cellectis Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia Business Wire
Nov-21-19 07:22AM  The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon Benzinga
Nov-20-19 04:30PM  Cellectis Wins Patent Challenge in Europe for a Method Using CRISPR-Cas9 for Gene Editing in T-Cells Business Wire
Nov-13-19 04:30PM  Cellectis Publishes Creation of Smart CAR T-Cells for Potentially Safer, More Effective Treatments for Cancer in Nature Communications Business Wire
Nov-06-19 04:47PM  Cellectis Reports Financial Results for Third Quarter and First Nine Months 2019 Business Wire
Oct-31-19 04:30PM  Cellectis to Hold Third Quarter and First Nine Months 2019 Earnings Call on Thursday, November 7, 2019 at 8:00 AM EST Business Wire
Oct-30-19 01:15AM  We're Keeping An Eye On Cellectis's (EPA:ALCLS) Cash Burn Rate Simply Wall St. +7.54%
Oct-29-19 04:30PM  First Patient Dosed with Off-the-Shelf UCARTCS1 Product Candidate for Relapsed/Refractory Multiple Myeloma Business Wire
Oct-04-19 01:02PM  2 Falling Knives Expected to Rebound GuruFocus.com
Oct-01-19 04:30PM  Cellectis and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis Allogeneic UCART Product Candidates Business Wire +7.02%
Sep-15-19 04:23AM  Does Cellectis S.A. (EPA:ALCLS) Have A Particularly Volatile Share Price? Simply Wall St.
Aug-06-19 04:30PM  Cellectis Reports Financial Results for Second Quarter and First Six Months 2019 Business Wire
Jul-08-19 04:30PM  Cellectis Publishes New CAR Design to Control CAR T-Cells in Non-Lethal Way Business Wire
Jun-26-19 04:30PM  Cellectis S.A. Reports Results from Combined Shareholders Meeting Held on June 25, 2019 Business Wire
May-07-19 04:32PM  Cellectis Reports Financial Results for First Quarter 2019 Business Wire
Apr-17-19 04:30PM  Cellectis Announces Oral and Poster Presentations of Allogeneic CAR T-Cell Programs at the 2019 ASGCT Annual Meeting Business Wire
Apr-03-19 08:19AM  The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings Benzinga
Apr-02-19 04:30PM  FDA Clears the IND for UCARTCS1, the First Allogeneic CAR-T to Treat Multiple Myeloma Patients Business Wire
Mar-11-19 04:10PM  Cellectis Reports 4th Quarter and Full Year 2018 Financial Results Business Wire
Mar-07-19 04:30PM  Cellectis Enters Lease Agreement to Build Manufacturing Facility, Advancing Towards Commercialization of its UCART Portfolio Business Wire
02:47PM  5 Top Gene-Editing Stocks for 2019 Motley Fool
Feb-25-19 05:10PM  Cellectis Publishes Novel Methods to Improve the Safety of CAR T-Cell Therapy and Prevent CRS in the Journal of Biological Chemistry Business Wire
Feb-07-19 07:25AM  Consolidated Research: 2019 Summary Expectations for Oceaneering International, Southwest Gas, WellCare Health Plans, Barnes & Noble, Cellectis S.A, and Payment Data Fundamental Analysis, Key Performance Indications GlobeNewswire
Dec-10-18 04:30PM  Cellectis Appoints William Monteith as Senior Vice President U.S. Manufacturing Business Wire
Nov-13-18 04:30PM  Cellectis Reports Financial Results for 3rd Quarter and First Nine Months 2018 Business Wire
Oct-17-18 08:10AM  New Research Coverage Highlights Esperion Therapeutics, Summit Therapeutics, Ocwen Financial, Keane Group, Cellectis S.A, and Rapid7 Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Sep-19-18 04:30PM  CAR-T Pioneer Dr. Stephan A. Grupp to Join Cellectis Clinical Advisory Board Business Wire
Sep-18-18 04:30PM  Calyxt Appoints CEO, Jim Blome, Former President & CEO of Bayer CropScience LP Business Wire
Aug-20-18 07:40AM  Report: Exploring Fundamental Drivers Behind Ballard Power, Reading International, Odonate Therapeutics, Stitch Fix, Summit Therapeutics, and Cellectis S.A New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Aug-02-18 04:30PM  Cellectis Appoints Stefan Scherer M.D., Ph.D., as Senior Vice President Clinical Development and Deputy Chief Medical Officer Business Wire
Aug-01-18 04:30PM  Cellectis Reports Financial Results for 2nd Quarter and First Six Months 2018 Business Wire
Jun-27-18 04:30PM  Cellectis S.A. Reports Results from Annual General Meeting Held on June 26, 2018 Business Wire
Jun-12-18 04:30PM  Cellectis Publishes Novel Methods to Improve the Clinical Use of Chimeric Antigen Receptor T-Cell Therapy in Scientific Reports Business Wire
Jun-08-18 09:56AM  Should Cellectis SA.s (NASDAQ:CLLS) Recent Earnings Decline Worry You? Simply Wall St.
Jun-05-18 07:35AM  Detailed Research: Economic Perspectives on Galapagos NV, Cellectis S.A, MediciNova, Logitech International S.A, The Descartes Systems Group, and Canadian Pacific Railway What Drives Growth in Today's Competitive Landscape GlobeNewswire
Jun-04-18 04:30PM  FDA Grants Cellectis IND Approval for UCART22 in B-ALL Business Wire
May-22-18 07:59PM  INSERTING and REPLACING: Approval of UCART123 Amendment in AML to Accelerate Clinical Development Business Wire
04:30PM  Cellectis: Approval of UCART123 Amendment in AML to Accelerate Clinical Development Business Wire
May-21-18 08:30AM  Cellectis S.A.: Calyxt Announces Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
May-15-18 05:50PM  Calyxt Announces Launch of Proposed Follow-On Offering Business Wire
May-10-18 05:15PM  Cellectis to Present Data at the 2018 ASGCT Annual Meeting Business Wire
07:30AM  Wired News - Atara Biotherapeutics Expands T-Cell Immunotherapy Collaboration with MSK to Develop Next-Generation CAR T Technologies ACCESSWIRE
May-07-18 04:30PM  Cellectis Reports 1st Quarter 2018 Financial Results Business Wire
May-02-18 04:30PM  Cellectis Files IND for UCART22 in Acute Lymphoblastic Leukemia (B-ALL) Business Wire
May-01-18 07:01AM  George Church, CRISPR Pioneer, Embraces Alternative Tech In Project To Recode A Human Genome Forbes
07:00AM  Harvards Wyss Institute Partners with Cellectis to Recode the Human Genome Business Wire
Apr-18-18 01:37AM  Should Cellectis SA.s (EPA:ALCLS) Recent Earnings Decline Worry You? Simply Wall St.
Apr-13-18 08:15AM  What Should We Expect From Cellectis SA.s (NASDAQ:CLLS) Earnings Over The Next Few Years? Simply Wall St.
Apr-11-18 07:40AM  Consolidated Research: 2018 Summary Expectations for Ctrip.com International, JA Solar Holdings, Co., Oaktree Specialty Lending, Rhythm Pharmaceuticals, Cellectis S.A, and Travelport Worldwide Fundamental Analysis, Key Performance Indications GlobeNewswire
01:50AM  Cellectis to Present Data at the 2018 AACR Annual Meeting Business Wire
Apr-10-18 04:10PM  Cellectis Announces Closing of Follow-On Offering Business Wire
Apr-07-18 08:34AM  Is Cellectis SA Stock a Buy Now? Motley Fool
Apr-06-18 08:45AM  Can Been-There Biotech Entrepreneur Arie Belldegrun Do It Yet Again? Motley Fool
Apr-05-18 04:34PM  Why Micron Technology, Mechel, and Cellectis Slumped Today Motley Fool -12.39%
08:05AM  Could Orgenesis (ORGS) be the Next Acquisition Target in Cell Therapy Space? ACCESSWIRE
Apr-04-18 08:30PM  Cellectis Announces Pricing of Follow-On Offering Business Wire -14.09%
Apr-03-18 05:45PM  Cellectis Announces Launch of Follow-On Offering Business Wire +25.38%
04:09PM  Pfizer Takes On Gilead, Novartis With New Deal In Cancer Drugs Investor's Business Daily
01:14PM  Pfizer in deal with Allogene to develop cancer cell therapies Reuters
08:10AM  Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate Development and Commercialization of Allogeneic Off-the-Shelf CAR T Therapies Business Wire
Mar-19-18 03:06AM  What Should Investors Know About Cellectis SA.s (EPA:ALCLS) Earnings Trend? Simply Wall St.
Mar-16-18 02:33PM  The Week Ahead In Biotech: Earnings, PDUFA Dates And More Benzinga
Mar-15-18 08:10AM  Report: Exploring Fundamental Drivers Behind Mountain Province Diamonds, Limoneira, Arsanis, ExlService, Argo Group International, and Cellectis S.A. New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Mar-13-18 04:30PM  Dr. Mathieu Simon to Retire as Cellectis Chief Operating Officer; Elsy Boglioli Named as Successor Business Wire
08:22AM  Cellectis SA.s (NASDAQ:CLLS) Profit Outlook Simply Wall St.
Mar-12-18 04:51PM  Cellectis Reports 4th Quarter and Full Year 2017 Financial Results Business Wire
Mar-08-18 04:30PM  Cellectis: Servier and Pfizer Announce Results of UCART19 First-in-Human Trials to Be Presented at the 44th EBMT (European Society for Blood and Marrow Transplantation) Annual Meeting Business Wire
Mar-05-18 12:00AM  [$$] Crispr gene editing ready for testing in humans Financial Times
Feb-13-18 12:01AM  Two Issued U.S. Patents Granted to Cellectis for CRISPR Use in T-Cells Business Wire
12:00AM  France's Cellectis wins U.S patents for gene editing technology Reuters
Jan-02-18 04:30PM  Cellectis to Present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 12:00 P.M. PT Business Wire
Dec-26-17 11:22AM  ETFs with exposure to Cellectis SA : December 26, 2017 Capital Cube
Dec-25-17 09:37AM  Cellectis SA :CLLS-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017 Capital Cube
Dec-14-17 10:28AM  Company News For Dec 14, 2017 Zacks
Dec-13-17 04:07PM  This Biotech Stock Rocketed On Human Trials For New Cancer Drug Investor's Business Daily
11:05AM  Why Cellectis Is Winning Big With Its Pfizer Partnership 24/7 Wall St.
Dec-12-17 06:38PM  Preliminary Data from Servier and Pfizers UCART19 Product Candidate Shows High Complete Remission Rate Across Two Phase I Adult and Pediatric Acute Lymphoblastic Leukemia Trials Business Wire
Dec-04-17 04:30PM  Cellectis Appoints Immuno-Oncology Leader Stéphane Depil to Position of Senior Vice President Research & Development and Chief Medical Officer Business Wire
04:30PM  Cellectis Appoints Elsy Boglioli to Executive Vice President, Strategy and Corporate Development Business Wire
Nov-30-17 07:40AM  Blog Exposure - Viking Therapeutics Reports Positive Top-Line Results from Phase-2 Study of VK5211 in Patients Recovering from Hip Fracture ACCESSWIRE
Nov-20-17 04:30PM  Cellectis Demonstrates Fine and Predictable Tuning of TALEN® Gene Editing Targeting to Improve T-cell Adoptive Immunotherapy Business Wire
Nov-15-17 11:42AM  ETFs with exposure to Cellectis SA : November 15, 2017 Capital Cube
Nov-14-17 07:00AM  Cellectis SA to Host Earnings Call ACCESSWIRE
Nov-13-17 04:15PM  Cellectis Reports Financial Results for Third Quarter and First Nine Months of 2017 Business Wire
Nov-09-17 08:28AM  Biotech Stock Roundup: Regeneron Delivers Strong Q3 Results, Cellectis Clinical Hold Lifted Zacks
Nov-06-17 07:00PM  FDA Lifts Clinical Hold on Cellectis Phase 1 Clinical Trials with UCART123 in AML and BPDCN Business Wire
Nov-03-17 12:03PM  ETFs with exposure to Cellectis SA : November 3, 2017 Capital Cube
Nov-01-17 04:15PM  Servier and Pfizer Announce Preliminary Results of the First-in-Human Trials of UCART19 Will Be Presented at the 59th American Society of Hematology (ASH) Annual Meeting Business Wire
04:15PM  Cellectis Announces Two Oral Presentations and One Poster Presentation at the 2017 ASH Annual Meeting Business Wire
Oct-24-17 09:36AM  ETFs with exposure to Cellectis SA : October 24, 2017 Capital Cube
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm. It is also developing UCARTCLL1 to treat AML; ALLO-819 for treating AML; UCARTCS1 for the treatment of multiple myeloma (MM); and ALLO-715 to treat MM. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; Cornell University; Dana Farber Cancer Institute; and H. Lee Moffitt Cancer Center. Cellectis S.A. was founded in 1999 and is based in Paris, France.
open in yahoo | open in reuters | open in google